A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors
OPEN TO ACCRUAL
I
NCT06750185
benedito.carneiro@BrownHealth.org
